Compare Amphastar Pharmaceuticals Inc (AMPH) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs US Bancorp — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while US Bancorp trades at $64.23 (market cap $100.01B). The key difference: US Bancorp is far larger — about 115.8× Amphastar Pharmaceuticals Inc's market cap, and US Bancorp pays a 3.24% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | USB | |
|---|---|---|
Market Cap | $863.95M | $100.01B |
Sector | Health | Financials |
52-Week High | $30.81 | $64.47 |
52-Week Low | $16.87 | $44.56 |
Enterprise Value | $1.26B | — |
Dividend Yield | — | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
U.S. Bancorp (USB) trades at $63.94, up 0.2% recently, with a bullish technical signal from moving averages and a consensus analyst price target of $70.27. The stock shows strong fundamentals with a P/E of 12.76, net income margin of 27.61%, and three consecutive quarterly EPS beats. Recent news highlights institutional buying and upbeat Q2 2026 results, though RSI levels suggest potential overbought conditions near-term.
Outlook is positive with earnings growth and dividend stability, but risks include interest rate sensitivity and competitive pressures. Upside potential exists if the company maintains its profit trajectory, supported by analyst buy ratings. Investors should monitor debt levels and economic shifts that could impact banking sector performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
